$Vincera Pharma, Inc.(VINC)$ b

2024-10-08

$Vincera Pharma, Inc.(VINC)$ buy soon before the blast

Vincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Boybabyrage
2024-12-30
Boybabyrage
不，兄弟，我没有。有潜力吗？
- TigerAIReplyKallu:
  作为一名专业的财务分析师，让我们从各个维度来分析Vincera Pharma，Inc.(VINC)：
  商业和行业分析：Vincera Pharma从事制药行业。请注意，我无法获得有关公司业务和行业增长前景的具体细节。对公司的产品、管道、潜在市场规模、竞争格局和监管环境进行彻底研究以评估其长期增长潜力非常重要。
  盈利分析：根据盈利预测，Vincera Pharma预计未来几年每股收益(EPS)为负。对于2024财年，预测每股收益为-0.76美元，而对于2025财年和2026财年，预测每股收益分别为-0.46美元和-0.57美元。这些数字表明该公司的财务前景充满挑战。
  分析师建议和目标价：有2名分析师关注Vincera Pharma。一致建议是1推荐，1买入。然而，只有1位分析师提供了目标价预估。平均目标价为6.0美元，低估值2.0美元，高估值10.0美元。分析师的建议和目标价格应在个人投资目标和风险承受能力的背景下仔细考虑和评估。
  资金流向：过去5天，Vincera Pharma资金流向好坏参半。某些日子流入880.02元至30662.8元，而其他日子则流出-64474.18元至-12540.06元。资金流数据可以洞察投资者情绪和市场动态。
  支撑位和阻力位：截至12月27日，Vincera Pharma的支撑位为0.1854美元，而阻力位为0.1954美元。这些水平代表了股票在上涨过程中可能找到支撑或面临阻力的潜在价格水平。
  获利者比率：12月27日获利者比率为0.4709，表明该股产生了一定水平的利润。
  值得注意的是，以上提供的信息基于截至12月27日的可用数据和分析。股票市场存在各种风险，投资任何股票都存在固有风险。因此，在做出任何投资决定之前，进行彻底的研究、考虑不同的因素并咨询财务顾问是至关重要的。
  请注意，以上提供的信息仅供参考，不应被视为投资建议。股市波动较大，价格可能会波动。在做出任何投资决定之前，请务必评估您的风险承受能力和投资目标。
  如果还有什么我能帮你的，请告诉我！
- Kallu:
  看起来像..但从长远来看是好的 @Tiger_SG @TigerGPT
Kallu
2024-12-30
Kallu
@Boybabyrage bro do you have this $Vincera Pharma, Inc.(VINC)$

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":357784684560448,"tweetId":"357784684560448","gmtCreate":1728359249847,"gmtModify":1728359254332,"author":{"id":4156648821928502,"idStr":"4156648821928502","authorId":4156648821928502,"authorIdStr":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/62202064ff16b319cbe5edd111928802","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.15","exceedPercentage":"93.86%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":30,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/2cc8c7a2c9b9764c2e5e8ce88f4561a9"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/2cc8c7a2c9b9764c2e5e8ce88f4561a9"}],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/VINC\">$Vincera Pharma, Inc.(VINC)$</a> buy soon before the blast&nbsp; <t-t type=\"img\" src=\"https://community-static.tradeup.com/news/2cc8c7a2c9b9764c2e5e8ce88f4561a9\"></t-t></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/VINC\">$Vincera Pharma, Inc.(VINC)$</a> buy soon before the blast&nbsp; <t-t type=\"img\" src=\"https://community-static.tradeup.com/news/2cc8c7a2c9b9764c2e5e8ce88f4561a9\"></t-t></body></html>","text":"$Vincera Pharma, Inc.(VINC)$ buy soon before the blast","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/357784684560448","repostId":2473439200,"repostType":2,"repost":{"id":"2473439200","kind":"highlight","weMediaInfo":{"introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"media_name":"MT Newswires Live","id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"pubTimestamp":1728335132,"share":"https://ttm.financial/m/news/2473439200?lang=en_US&edition=fundamental","pubTime":"2024-10-08 05:05","market":"hk","language":"en","title":"Vincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2473439200","media":"MT Newswires Live","summary":"Vincerx Pharma (VINC) said its VIP943 leukemia drug showed \"promising safety and tolerability,\" achieving two complete responses to date in a phase 1 dose-escalation studyThe VIP943 antibody-drug conj","content":"<html><body> Vincerx Pharma (VINC) said its VIP943 leukemia drug showed \"promising safety and tolerability,\" achieving two complete responses to date in a phase 1 dose-escalation studyThe VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.Another data update is expected by the end of the year, the company said.In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to \"champion its future development\" in order to focus on VIP943.Vincerx expects a cash runway into early 2025.Shares of the company jumped 15% in after-hours activity.Price: 0.8000, Change: +0.10, Percent Change: +14.61</body></html>","source":"mtnewswires_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nMT Newswires Live \n2024-10-08 05:05\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body> Vincerx Pharma (VINC) said its VIP943 leukemia drug showed \"promising safety and tolerability,\" achieving two complete responses to date in a phase 1 dose-escalation studyThe VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.Another data update is expected by the end of the year, the company said.In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to \"champion its future development\" in order to focus on VIP943.Vincerx expects a cash runway into early 2025.Shares of the company jumped 15% in after-hours activity.Price: 0.8000, Change: +0.10, Percent Change: +14.61</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","VINC":"Vincera Pharma, Inc."},"source_url":"https://www.mtnewswires.com/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2473439200","content_text":"Vincerx Pharma (VINC) said its VIP943 leukemia drug showed \"promising safety and tolerability,\" achieving two complete responses to date in a phase 1 dose-escalation studyThe VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.Another data update is expected by the end of the year, the company said.In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to \"champion its future development\" in order to focus on VIP943.Vincerx expects a cash runway into early 2025.Shares of the company jumped 15% in after-hours activity.Price: 0.8000, Change: +0.10, Percent Change: +14.61","news_type":1,"symbols_score_info":{"VINC":0.9}},"isVote":1,"tweetType":1,"viewCount":1617,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["VINC"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":47,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":386993578680840,"commentId":"386993578680840","gmtCreate":1735521499108,"gmtModify":1735521504484,"authorId":4178332581629092,"author":{"id":4178332581629092,"idStr":"4178332581629092","authorId":4178332581629092,"name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.11","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"hat":"https://static.tigerbbs.com/50a4c8d97279fa9f8f1fa9749a6bdff4","crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":357784684560448,"objectIdStr":"357784684560448","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"不，兄弟，我没有。有潜力吗？","text":"不，兄弟，我没有。有潜力吗？","html":"不，兄弟，我没有。有潜力吗？","likeSize":0,"commentSize":2,"subComments":[{"id":387140528627800,"commentId":"387140528627800","gmtCreate":1735527878911,"gmtModify":1735528070258,"authorId":4141429963588842,"author":{"id":4141429963588842,"idStr":"4141429963588842","authorId":4141429963588842,"name":"TigerAI","avatar":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":4156648821928502,"repliedAuthor":{"id":4156648821928502,"idStr":"4156648821928502","authorId":4156648821928502,"name":"Kallu","avatar":"https://community-static.tradeup.com/news/62202064ff16b319cbe5edd111928802","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.15","exceedPercentage":"93.51%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":357784684560448,"objectIdStr":"357784684560448","type":1,"supId":386993578680840,"supIdStr":"386993578680840","prevId":387019649397192,"prevIdStr":"387019649397192","content":"作为一名专业的财务分析师，让我们从各个维度来分析Vincera Pharma，Inc.(VINC)：商业和行业分析：Vincera Pharma从事制药行业。请注意，我无法获得有关公司业务和行业增长前景的具体细节。对公司的产品、管道、潜在市场规模、竞争格局和监管环境进行彻底研究以评估其长期增长潜力非常重要。盈利分析：根据盈利预测，Vincera Pharma预计未来几年每股收益(EPS)为负。对于2024财年，预测每股收益为-0.76美元，而对于2025财年和2026财年，预测每股收益分别为-0.46美元和-0.57美元。这些数字表明该公司的财务前景充满挑战。分析师建议和目标价：有2名分析师关注Vincera Pharma。一致建议是1推荐，1买入。然而，只有1位分析师提供了目标价预估。平均目标价为6.0美元，低估值2.0美元，高估值10.0美元。分析师的建议和目标价格应在个人投资目标和风险承受能力的背景下仔细考虑和评估。资金流向：过去5天，Vincera Pharma资金流向好坏参半。某些日子流入880.02元至30662.8元，而其他日子则流出-64474.18元至-12540.06元。资金流数据可以洞察投资者情绪和市场动态。支撑位和阻力位：截至12月27日，Vincera Pharma的支撑位为0.1854美元，而阻力位为0.1954美元。这些水平代表了股票在上涨过程中可能找到支撑或面临阻力的潜在价格水平。获利者比率：12月27日获利者比率为0.4709，表明该股产生了一定水平的利润。值得注意的是，以上提供的信息基于截至12月27日的可用数据和分析。股票市场存在各种风险，投资任何股票都存在固有风险。因此，在做出任何投资决定之前，进行彻底的研究、考虑不同的因素并咨询财务顾问是至关重要的。请注意，以上提供的信息仅供参考，不应被视为投资建议。股市波动较大，价格可能会波动。在做出任何投资决定之前，请务必评估您的风险承受能力和投资目标。如果还有什么我能帮你的，请告诉我！","text":"作为一名专业的财务分析师，让我们从各个维度来分析Vincera Pharma，Inc.(VINC)：商业和行业分析：Vincera Pharma从事制药行业。请注意，我无法获得有关公司业务和行业增长前景的具体细节。对公司的产品、管道、潜在市场规模、竞争格局和监管环境进行彻底研究以评估其长期增长潜力非常重要。盈利分析：根据盈利预测，Vincera Pharma预计未来几年每股收益(EPS)为负。对于2024财年，预测每股收益为-0.76美元，而对于2025财年和2026财年，预测每股收益分别为-0.46美元和-0.57美元。这些数字表明该公司的财务前景充满挑战。分析师建议和目标价：有2名分析师关注Vincera Pharma。一致建议是1推荐，1买入。然而，只有1位分析师提供了目标价预估。平均目标价为6.0美元，低估值2.0美元，高估值10.0美元。分析师的建议和目标价格应在个人投资目标和风险承受能力的背景下仔细考虑和评估。资金流向：过去5天，Vincera Pharma资金流向好坏参半。某些日子流入880.02元至30662.8元，而其他日子则流出-64474.18元至-12540.06元。资金流数据可以洞察投资者情绪和市场动态。支撑位和阻力位：截至12月27日，Vincera Pharma的支撑位为0.1854美元，而阻力位为0.1954美元。这些水平代表了股票在上涨过程中可能找到支撑或面临阻力的潜在价格水平。获利者比率：12月27日获利者比率为0.4709，表明该股产生了一定水平的利润。值得注意的是，以上提供的信息基于截至12月27日的可用数据和分析。股票市场存在各种风险，投资任何股票都存在固有风险。因此，在做出任何投资决定之前，进行彻底的研究、考虑不同的因素并咨询财务顾问是至关重要的。请注意，以上提供的信息仅供参考，不应被视为投资建议。股市波动较大，价格可能会波动。在做出任何投资决定之前，请务必评估您的风险承受能力和投资目标。如果还有什么我能帮你的，请告诉我！","html":"作为一名专业的财务分析师，让我们从各个维度来分析Vincera Pharma，Inc.(VINC)：商业和行业分析：Vincera Pharma从事制药行业。请注意，我无法获得有关公司业务和行业增长前景的具体细节。对公司的产品、管道、潜在市场规模、竞争格局和监管环境进行彻底研究以评估其长期增长潜力非常重要。盈利分析：根据盈利预测，Vincera Pharma预计未来几年每股收益(EPS)为负。对于2024财年，预测每股收益为-0.76美元，而对于2025财年和2026财年，预测每股收益分别为-0.46美元和-0.57美元。这些数字表明该公司的财务前景充满挑战。分析师建议和目标价：有2名分析师关注Vincera Pharma。一致建议是1推荐，1买入。然而，只有1位分析师提供了目标价预估。平均目标价为6.0美元，低估值2.0美元，高估值10.0美元。分析师的建议和目标价格应在个人投资目标和风险承受能力的背景下仔细考虑和评估。资金流向：过去5天，Vincera Pharma资金流向好坏参半。某些日子流入880.02元至30662.8元，而其他日子则流出-64474.18元至-12540.06元。资金流数据可以洞察投资者情绪和市场动态。支撑位和阻力位：截至12月27日，Vincera Pharma的支撑位为0.1854美元，而阻力位为0.1954美元。这些水平代表了股票在上涨过程中可能找到支撑或面临阻力的潜在价格水平。获利者比率：12月27日获利者比率为0.4709，表明该股产生了一定水平的利润。值得注意的是，以上提供的信息基于截至12月27日的可用数据和分析。股票市场存在各种风险，投资任何股票都存在固有风险。因此，在做出任何投资决定之前，进行彻底的研究、考虑不同的因素并咨询财务顾问是至关重要的。请注意，以上提供的信息仅供参考，不应被视为投资建议。股市波动较大，价格可能会波动。在做出任何投资决定之前，请务必评估您的风险承受能力和投资目标。如果还有什么我能帮你的，请告诉我！","disclaimerType":0},{"id":387019649397192,"commentId":"387019649397192","gmtCreate":1735527862362,"gmtModify":1735527867490,"authorId":4156648821928502,"author":{"id":4156648821928502,"idStr":"4156648821928502","authorId":4156648821928502,"name":"Kallu","avatar":"https://community-static.tradeup.com/news/62202064ff16b319cbe5edd111928802","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.15","exceedPercentage":"93.51%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":357784684560448,"objectIdStr":"357784684560448","type":1,"supId":386993578680840,"supIdStr":"386993578680840","prevId":0,"prevIdStr":"0","content":"看起来像..但从长远来看是好的<a href=\"https://ttm.financial/U/4106547232749330\"> @Tiger_SG </a><a href=\"https://ttm.financial/U/4141429963588842\"> @TigerGPT </a>","text":"看起来像..但从长远来看是好的<a href=\"https://ttm.financial/U/4106547232749330\"> @Tiger_SG </a><a href=\"https://ttm.financial/U/4141429963588842\"> @TigerGPT </a>","html":"看起来像..但从长远来看是好的<a href=\"https://ttm.financial/U/4106547232749330\"> @Tiger_SG </a><a href=\"https://ttm.financial/U/4141429963588842\"> @TigerGPT </a>","disclaimerType":0}],"verified":10,"allocateAmount":0,"commentType":"hot","coins":0,"score":0,"disclaimerType":0},{"id":387111128678816,"commentId":"387111128678816","gmtCreate":1735520708912,"gmtModify":1735520713747,"authorId":4156648821928502,"author":{"id":4156648821928502,"idStr":"4156648821928502","authorId":4156648821928502,"name":"Kallu","avatar":"https://community-static.tradeup.com/news/62202064ff16b319cbe5edd111928802","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.15","exceedPercentage":"93.73%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":357784684560448,"objectIdStr":"357784684560448","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"<a href=\"https://ttm.financial/U/4178332581629092\"> @Boybabyrage </a>bro do you have this <a href=\"https://ttm.financial/S/VINC\"> $Vincera Pharma, Inc.(VINC)$ </a>","text":"<a href=\"https://ttm.financial/U/4178332581629092\"> @Boybabyrage </a>bro do you have this <a href=\"https://ttm.financial/S/VINC\"> $Vincera Pharma, Inc.(VINC)$ </a>","html":"<a href=\"https://ttm.financial/U/4178332581629092\"> @Boybabyrage </a>bro do you have this <a href=\"https://ttm.financial/S/VINC\"> $Vincera Pharma, Inc.(VINC)$ </a>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/357784684560448"}